Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021)
Climb Bio's (CLYM) quarterly Preferred Stock Liabilities came in at $152.8 million in Q2 2021, up 464.42% YoY from $27.1 million in Q2 2020, and up 64.61% on a QoQ basis from $92.8 million in Q1 2021.
Powered by 
Analysis
Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Climb Bio (CLYM) has 2 years of Preferred Stock Liabilities data on file, last reported at $152.8 million in Q2 2021.
- Quarterly Preferred Stock Liabilities rose 464.42% year-over-year to $152.8 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $152.8 million (up 464.42% YoY) and the FY2020 annual result came in at $46.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $152.8 million in Q2 2021, from $92.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $152.8 million in Q2 2021 to a low of $27.1 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 152.76 Mn |
| Mar 31, 2021 | 92.80 Mn |
| Dec 31, 2020 | 46.55 Mn |
| Sep 30, 2020 | 27.53 Mn |
| Jun 30, 2020 | 27.07 Mn |